Flexion Therapeutics shares soar after FDA approves change to label on knee pain treatment

Shares of Flexion Therapeutics Inc. soared 14% Friday, after the company said the U.S. Food and Drug Administration has approved an update to the label on its Zilretta treatment for osteoarthritis (OA) knee pain that analysts said should help it get reimbursement from insurers and boost sales.